查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1914699

核子醫學市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、診斷核子醫學、治療核子醫學、應用、最終用戶、地區和競爭格局分類），2021-2031年

Nuclear Medicine Market - Global Industry Size, Share, Trends, Opportunity and Forecast Segmented By Type, By Diagnostic Nuclear Medicine, By Therapeutic Nuclear Medicine, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球核子醫學產業預計將從2025年的101.9億美元顯著成長至2031年的193.4億美元，複合年成長率（CAGR）達11.27%。這個專業醫學領域利用放射性藥物評估生理過程，並透過標靶分子介入來治療疾病。推動市場成長的主要因素是全球人口快速老化以及由此導致的癌症和心血管疾病等慢性病發病率上升，這些疾病需要高度精準的診斷和治療能力。這些流行病學和人口統計趨勢確保了對核醫學影像和放射性核素治療的持續需求，使其區別於暫時的市場趨勢。

市場概覽
預測期 2027-2031
市場規模：2025年 101.9億美元
市場規模：2031年 193.4億美元
複合年成長率：2026-2031年 11.27%
成長最快的細分市場 治療性核子醫學
最大的市場 北美洲

儘管該行業潛力巨大，但在供應鏈可靠性方面仍面臨嚴峻挑戰，尤其是診斷所需的短壽命放射性同位素的持續供應。這些關鍵材料的生產嚴重依賴數量有限的老舊研究核子反應爐，使得供應鏈極易受到物流中斷的影響。歐洲核子醫學會（Nuclear Medicine Europe）指出，2024年底計畫外的核子反應爐維護可能導致關鍵診斷用同位素發生器供不應求40%，凸顯了全球分銷體系的脆弱性。

市場促進因素

治療性診斷（治療診斷學）和精準醫療的快速發展是市場擴張的主要驅動力，推動產業從簡單的​​診斷影像轉向綜合治療策略。這種將診斷生物標記與治療性放射性同位素結合的調查方法，在腫瘤學領域取得了顯著的商業性成功，尤其是在前列腺癌和神經內分泌腫瘤的治療方面。領先的放射性配體療法的優異表現證明了這一趨勢的強勁經濟實力。例如，諾華公司在2024年第三季財報中揭露，其前列腺癌藥物Pulvict的全球銷售額在該季度達到3.86億美元，較去年同期成長50%。因此，各大製藥公司正迅速加大對該領域的投資。例如，百時美施貴寶公司於2024年2月以約41億美元收購了RaizeBio公司，以確保其基於錒系元素的放射性藥物產品線，這印證了該行業向靶向α療法的轉型。

同時，同位素生產技術和放射性藥物供應鏈的進步正在降低對傳統核子反應爐的依賴。為了解決先進治療所需的α發射體供不應求和國際分銷不穩定的問題，對粒子加速器等替代生產技術的投資顯著增加。近期歐洲基礎設施的資金籌措凸顯了這個結構性轉變。 2024年9月，PanTera NV宣布獲得9,300萬歐元的A輪資金籌措，用於在比利時早期建立一座商業規模的錒-225生產廠。這種產能的提升對於確保穩定同位素的供應、降低物流風險以及實現新型核醫藥物的永續商業化至關重要。

市場挑戰

全球核子醫學市場發展面臨的主要障礙之一是供應鏈的持續不穩定，尤其是在短壽命放射性同位素的生產方面。與標準藥品不同，鉬-99等同位素由於其放射性崩壞迅速而無法儲存，因此需要一個完美無缺的「即時」全球配送系統。目前，這個配送網路依賴數量日益減少的研究用核子反應爐，這些反應器老化嚴重，結構故障和計劃外維護的風險也越來越高。如果這些關鍵設施運作，診斷試劑短缺將迫使醫療機構推遲或取消檢查，直接影響患者數量和收入來源。

這種運作可靠性的缺失嚴重限制了市場成長，削弱了醫院管理者和醫生的信心。面對不穩定的供應計劃，醫療專業人員可能會將患者轉介至其他診斷方式，例如CT和MRI，減緩核醫影像技術的普及。這種依賴性在主要市場尤為突出。例如，核子醫學與分子影像學會（SNMMI）2024年的報告顯示，美國超過80%的Technetium-99m供應依賴海外進口，這使得該產業極易受到國際物流中斷的影響。

市場趨勢

放射性藥物在神經病學領域的應用不斷擴展，正在改變整個市場模式。這主要得益於阿茲海默症緩解疾病療法的出現，而這些療法需要精準的分子影像技術。這一趨勢不再局限於傳統的腫瘤治療領域，而是依賴BETA-澱粉樣蛋白正子斷層掃描（PET）檢測在患者合格和治療後續觀察的關鍵作用。這種臨床需求導致診斷量激增，也印證了非腫瘤應用領域的拓展。例如，Fierce Pharma在2025年2月發布的報告顯示，衛材公司（Eisai）在美國2024年第四季的BETA-澱粉樣蛋白PET檢測量增加了45%，這表明治療方案的普及與診斷需求之間存在直接關聯。

同時，隨著相關人員尋求透過穩健、一體化的基礎設施來降低供應鏈風險，合約研發生產機構（CDMO）的重要性日益凸顯，並正成為產業結構的重要組成部分。領先的醫療機構和投資者越來越重視能夠確保可靠的複雜同位素生產和全球供應的垂直整合型製造商。這種重視體現在近期的財務活動中，例如Curium Pharma在2025年11月宣布已完成一項資本重組協議，公司估值約為70億美元，凸顯了該公司對其可擴展生產能力的高度重視。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球核子醫學市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（診斷性核子醫學和治療性核子醫學）
    • 透過診斷性核子醫學（SPECT 和 PET 放射性藥物）
    • 治療性核子醫學（BETA射線發射體、α射線發射體和近距離放射治療同位素）
    • 依應用領域（腫瘤科、心臟科、神經科、其他）
    • 依最終使用者（醫院/診所、診斷中心、學術/研究機構、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美核子醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲核子醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區核子醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲核子醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美核子醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球核子醫學市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Cardinal Health, Inc.
  • Curium SAS
  • GE Healthcare, Inc.
  • Novartis AG
  • Lantheus Medical Imaging, Inc.
  • Bayer AG
  • Bracco Imaging SpA
  • Nordion Inc.
  • Isotopia Molecular Imaging Limited
  • NorthStar Medical Radioisotopes, LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 4562

The Global Nuclear Medicine industry is projected to expand significantly, rising from USD 10.19 Billion in 2025 to USD 19.34 Billion by 2031, achieving a CAGR of 11.27%. This specialized medical field utilizes radiopharmaceuticals to evaluate physiological processes and manage diseases through targeted molecular interventions. The market's foundational growth is driven by a rapidly aging global demographic and an associated increase in chronic illnesses, such as cancer and cardiovascular diseases, which necessitate high-precision diagnostic and therapeutic capabilities. These epidemiological and demographic trends guarantee a lasting demand for nuclear imaging and radionuclide therapies, distinguishing them from temporary market fads.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 10.19 Billion
Market Size 2031USD 19.34 Billion
CAGR 2026-203111.27%
Fastest Growing SegmentTherapeutic Nuclear Medicine
Largest MarketNorth America

Despite this potential, the sector encounters major obstacles related to supply chain reliability, specifically the continuous availability of short-lived radioisotopes essential for diagnostics. Producing these vital materials depends heavily on a small number of aging research reactors, leaving the supply chain exposed to logistical interruptions. Highlighting this fragility, Nuclear Medicine Europe reported that unexpected reactor maintenance in late 2024 was expected to result in supply shortages reaching 40% for critical diagnostic isotope generators, underscoring the instability of the global distribution framework.

Market Driver

The swift growth of theranostics and precision medicine serves as a major accelerator for market expansion, transitioning the industry from solely diagnostic imaging to comprehensive therapeutic strategies. This methodology, which combines diagnostic biomarkers with therapeutic radioisotopes, has achieved significant commercial success, especially in oncology for managing prostate and neuroendocrine tumors. The financial strength of this trend is demonstrated by the performance of top radioligand therapies; for example, Novartis revealed in its Q3 2024 results that global revenue for its prostate cancer treatment, Pluvicto, hit $386 million in that quarter, marking a 50% increase year-over-year. Accordingly, leading pharmaceutical companies are rapidly investing in this sector, as seen in Bristol Myers Squibb's acquisition of RayzeBio for roughly $4.1 billion in February 2024 to secure an actinium-based radiopharmaceutical pipeline, confirming the industry's shift toward targeted alpha therapies.

Concurrently, advancements in isotope production and the radiopharmaceutical supply chain are developing to reduce the historic dependence on older nuclear reactors. To counter the instability of global distribution and the shortage of alpha-emitters needed for advanced therapies, there is a notable increase in investments toward alternative manufacturing techniques, such as particle accelerators. This structural evolution is highlighted by recent funding for European infrastructure; PanTera NV announced in September 2024 that it secured €93 million in Series A funding to fast-track the creation of a commercial-scale Actinium-225 production plant in Belgium. Such enhancements in production capacity are vital for guaranteeing a consistent isotope supply, thereby diminishing logistical risks and enabling the sustainable commercial launch of novel nuclear medicine agents.

Market Challenge

The central hurdle obstructing the Global Nuclear Medicine market's progress is the ongoing volatility of its supply chain, specifically concerning the manufacture of short-lived radioisotopes. In contrast to standard drugs, isotopes like Molybdenum-99 cannot be stored due to rapid radioactive decay, requiring a flawless "just-in-time" global delivery system. This network currently depends on a shrinking group of aging research reactors that are increasingly susceptible to structural breakdowns and unplanned maintenance. When these essential facilities become inoperative, the resulting shortage of diagnostic agents compels healthcare providers to delay or annul procedures, directly impacting patient volume and revenue streams.

This lack of operational reliability significantly restricts market growth by undermining the trust of hospital administrators and physicians. Confronted with erratic supply schedules, medical practitioners may redirect patients toward other diagnostic methods such as CT or MRI, effectively slowing the uptake of nuclear imaging technologies. The gravity of this reliance is particularly severe in key markets; for instance, the Society of Nuclear Medicine and Molecular Imaging reported in 2024 that the United States depended on foreign imports for more than 80% of its Technetium-99m supply, rendering the industry extremely susceptible to disruptions in international logistics.

Market Trends

The extension of radiopharmaceutical utility into neurology is significantly transforming the market, fueled by the release of disease-modifying Alzheimer's treatments that require accurate molecular imaging. Departing from the sector's traditional focus on oncology, this trend relies on the essential function of amyloid-beta positron emission tomography (PET) scans for qualifying patients and monitoring treatment. This clinical requirement has triggered an immediate rise in diagnostic volumes, confirming the movement toward non-cancer applications. As an illustration, Fierce Pharma reported in February 2025 that Eisai observed a 45% surge in amyloid beta PET testing volumes within the United States during the last quarter of 2024, showing a direct link between therapeutic uptake and diagnostic demand.

At the same time, the increasing importance of Contract Development and Manufacturing Organizations (CDMOs) is becoming a fundamental component of the industry structure, as stakeholders aim to reduce supply chain risks through robust, consolidated infrastructure. Major healthcare organizations and investors are placing higher value on vertically integrated manufacturers capable of ensuring reliable complex isotope production and global delivery. This appreciation is reflected in recent financial activities; for example, Curium Pharma announced in November 2025 that it completed a recapitalization deal valuing the enterprise at roughly $7 billion, highlighting the premium attached to scalable manufacturing competencies.

Key Market Players

  • Cardinal Health, Inc.
  • Curium SAS
  • GE Healthcare, Inc.
  • Novartis AG
  • Lantheus Medical Imaging, Inc.
  • Bayer AG
  • Bracco Imaging S.p.A
  • Nordion Inc.
  • Isotopia Molecular Imaging Limited
  • NorthStar Medical Radioisotopes, LLC

Report Scope

In this report, the Global Nuclear Medicine market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nuclear Medicine market, By Type

  • Diagnostic Nuclear Medicine & Therapeutic Nuclear Medicine

Nuclear Medicine market, By Diagnostic Nuclear Medicine

  • SPECT & PET Radiopharmaceuticals

Nuclear Medicine market, By Therapeutic Nuclear Medicine

  • Beta Emitters
  • Alpha Emitters & Brachytherapy Isotopes

Nuclear Medicine market, By Application

  • Oncology
  • Cardiology
  • Neurology
  • Others

Nuclear Medicine market, By End User

  • Hospitals & Clinics
  • Diagnostic Centers
  • Academic & Research Institutions
  • Others

Nuclear Medicine market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Nuclear Medicine market.

Available Customizations:

Global Nuclear Medicine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nuclear Medicine market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Diagnostic Nuclear Medicine & Therapeutic Nuclear Medicine)
    • 5.2.2. By Diagnostic Nuclear Medicine (SPECT & PET Radiopharmaceuticals)
    • 5.2.3. By Therapeutic Nuclear Medicine (Beta Emitters, Alpha Emitters & Brachytherapy Isotopes)
    • 5.2.4. By Application (Oncology, Cardiology, Neurology, Others)
    • 5.2.5. By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Nuclear Medicine market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Diagnostic Nuclear Medicine
    • 6.2.3. By Therapeutic Nuclear Medicine
    • 6.2.4. By Application
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Nuclear Medicine market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Diagnostic Nuclear Medicine
        • 6.3.1.2.3. By Therapeutic Nuclear Medicine
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Nuclear Medicine market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Diagnostic Nuclear Medicine
        • 6.3.2.2.3. By Therapeutic Nuclear Medicine
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Nuclear Medicine market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Diagnostic Nuclear Medicine
        • 6.3.3.2.3. By Therapeutic Nuclear Medicine
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End User

7. Europe Nuclear Medicine market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Diagnostic Nuclear Medicine
    • 7.2.3. By Therapeutic Nuclear Medicine
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Nuclear Medicine market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Diagnostic Nuclear Medicine
        • 7.3.1.2.3. By Therapeutic Nuclear Medicine
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. France Nuclear Medicine market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Diagnostic Nuclear Medicine
        • 7.3.2.2.3. By Therapeutic Nuclear Medicine
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Nuclear Medicine market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Diagnostic Nuclear Medicine
        • 7.3.3.2.3. By Therapeutic Nuclear Medicine
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Nuclear Medicine market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Diagnostic Nuclear Medicine
        • 7.3.4.2.3. By Therapeutic Nuclear Medicine
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Nuclear Medicine market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Diagnostic Nuclear Medicine
        • 7.3.5.2.3. By Therapeutic Nuclear Medicine
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End User

8. Asia Pacific Nuclear Medicine market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Diagnostic Nuclear Medicine
    • 8.2.3. By Therapeutic Nuclear Medicine
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Nuclear Medicine market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Diagnostic Nuclear Medicine
        • 8.3.1.2.3. By Therapeutic Nuclear Medicine
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. India Nuclear Medicine market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Diagnostic Nuclear Medicine
        • 8.3.2.2.3. By Therapeutic Nuclear Medicine
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Nuclear Medicine market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Diagnostic Nuclear Medicine
        • 8.3.3.2.3. By Therapeutic Nuclear Medicine
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Nuclear Medicine market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Diagnostic Nuclear Medicine
        • 8.3.4.2.3. By Therapeutic Nuclear Medicine
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Nuclear Medicine market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Diagnostic Nuclear Medicine
        • 8.3.5.2.3. By Therapeutic Nuclear Medicine
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. Middle East & Africa Nuclear Medicine market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Diagnostic Nuclear Medicine
    • 9.2.3. By Therapeutic Nuclear Medicine
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Nuclear Medicine market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Diagnostic Nuclear Medicine
        • 9.3.1.2.3. By Therapeutic Nuclear Medicine
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. UAE Nuclear Medicine market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Diagnostic Nuclear Medicine
        • 9.3.2.2.3. By Therapeutic Nuclear Medicine
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. South Africa Nuclear Medicine market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Diagnostic Nuclear Medicine
        • 9.3.3.2.3. By Therapeutic Nuclear Medicine
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User

10. South America Nuclear Medicine market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Diagnostic Nuclear Medicine
    • 10.2.3. By Therapeutic Nuclear Medicine
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Nuclear Medicine market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Diagnostic Nuclear Medicine
        • 10.3.1.2.3. By Therapeutic Nuclear Medicine
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Colombia Nuclear Medicine market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Diagnostic Nuclear Medicine
        • 10.3.2.2.3. By Therapeutic Nuclear Medicine
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. Argentina Nuclear Medicine market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Diagnostic Nuclear Medicine
        • 10.3.3.2.3. By Therapeutic Nuclear Medicine
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Nuclear Medicine market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Cardinal Health, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Curium SAS
  • 15.3. GE Healthcare, Inc.
  • 15.4. Novartis AG
  • 15.5. Lantheus Medical Imaging, Inc.
  • 15.6. Bayer AG
  • 15.7. Bracco Imaging S.p.A
  • 15.8. Nordion Inc.
  • 15.9. Isotopia Molecular Imaging Limited
  • 15.10. NorthStar Medical Radioisotopes, LLC

16. Strategic Recommendations

17. About Us & Disclaimer